Publications by authors named "Erin B Kennedy"
Purpose: To provide evidence-based guidance for clinicians who treat patients with stage I-III anal cancer.
Methods: A systematic review of the literature conducted by the Minnesota Evidence-based Practice Center provided the evidence base for this guideline. An ASCO Expert Panel reviewed this evidence and came to consensus on a set of evidence-based recommendations.
. .PURPOSETo provide evidence-based guidance for clinicians who treat patients with locally advanced rectal cancer.
View Article and Find Full Text PDFPurpose: To update an evidence-based guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma (HCC).
Methods: ASCO convened an Expert Panel to update the 2020 guideline on systemic therapy for HCC. The panel updated the systematic review to include randomized controlled trials (RCTs) published through October 2023 and updated recommendations.
Purpose: To develop recommendations for systemic therapy for well-differentiated grade 1 (G1) to grade 3 (G3) metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Methods: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice.
Results: Eight randomized controlled trials met the inclusion criteria for the systematic review.
Purpose: To develop recommendations involving targeted therapies for patients with advanced gastroesophageal cancer.
Methods: The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice.
Results: Eighteen randomized controlled trials met the inclusion criteria for the systematic review.
Purpose: To develop recommendations for treatment of patients with metastatic colorectal cancer (mCRC).
Methods: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice.
Results: Five systematic reviews and 10 randomized controlled trials met the systematic review inclusion criteria.
Purpose: To develop recommendations for adjuvant therapy for patients with resected stage II colon cancer.
Methods: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice.
Results: Twenty-one observational studies and six randomized controlled trials met the systematic review inclusion criteria.
Purpose: To provide standards and practice recommendations specific to telehealth in oncology.
Methods: A systematic review of the literature on telehealth in oncology was performed, including the use of technologies and telecommunications systems, and other electronic methods of care delivery and sharing of information with patients. The evidence base was combined with the opinion of the ASCO Telehealth Expert Panel to develop telehealth standards and guidance.
Purpose: To provide Standards on the basis of evidence and expert consensus for a pilot of the Oncology Medical Home (OMH) certification program. The OMH model is a system of care delivery that features coordinated, efficient, accessible, and evidence-based care and includes a process for measurement of outcomes to facilitate continuous quality improvement. The OMH pilot is intended to inform further refinement of Standards for OMH model implementation.
View Article and Find Full Text PDFPurpose: To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with advanced hepatocellular carcinoma (HCC).
Methods: ASCO convened an Expert Panel to conduct a systematic review of published phase III randomized controlled trials (2007-2020) on systemic therapy for advanced HCC and provide recommended care options for this patient population.
Results: Nine phase III randomized controlled trials met the inclusion criteria.
Article Synopsis
- - The work updates ASCO's guidelines on how to treat metastatic pancreatic cancer after the first line of therapy, focusing on new second-line options.
- - An Expert Panel conducted a systematic review, finding key studies on treating the disease with drugs like olaparib and larotrectinib to support the guideline changes.
- - New recommendations include genetic testing for specific mutations to help determine the best therapies for patients, while still endorsing earlier second-line chemotherapy approaches and overall treatment strategies.
Purpose: To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with locally advanced esophageal cancer.
Methods: ASCO convened an Expert Panel to conduct a systematic review of the more recently published literature (1999-2019) on therapy options for patients with locally advanced esophageal cancer and provide recommended care options for this patient population.
Results: Seventeen randomized controlled trials met the inclusion criteria.
Purpose: To provide standards for medically integrated dispensing of oral anticancer drugs and supportive care medications.
Methods: An Expert Panel was formed, and a systematic review of the literature on patient-centered best practices for the delivery of oral anticancer and supportive care drugs was performed to April 2019 using PubMed and Google Scholar. Available patient-centered standards, including one previously developed by the National Community Oncology Dispensing Association (NCODA), were considered for endorsement.
Objective: To determine whether younger oocyte donor age is associated with better outcomes after in vitro fertilization (IVF) compared with older oocyte donor age.
Design: A retrospective cohort study.
Setting: Large academically affiliated infertility treatment center.
Purpose: To develop recommendations for duration of adjuvant chemotherapy with a fluoropyrimidine and oxaliplatin for patients with completely resected stage III colon cancer based on the results of trials of 3 months compared with 6 months of treatment.
Methods: ASCO convened an Expert Panel and conducted a systematic review of relevant studies. The guideline recommendations were based on the review of evidence by the Expert Panel.
Purpose: To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer.
Methods: ASCO convened an Expert Panel to conduct a systematic review of the literature on adjuvant therapy for resected biliary tract cancer and provide recommended care options for this patient population.
Results: Three phase III randomized controlled trials, one phase II trial, and 16 retrospective studies met the inclusion criteria.